Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.79 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.63 |
| ▸ | BACE1 | P56817 | 1/20 | 0.62 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL634206 | 1.00 | NR1H4 (0.79) | NR1H4CHRNA7BACE1NFE2L2MEN1 | |
| SCHEMBL5138238 | 0.91 | MAPT (0.71) | NR1H4NFE2L2MEN1KMT2AABCG2 | |
| SCHEMBL5138233 | 0.91 | MAPT (0.71) | NR1H4NFE2L2MEN1KMT2AABCG2 | |
| SCHEMBL4046463 | 0.88 | NR1H4 (1.00) | NR1H4CHRNA7BACE1MEN1KMT2A | |
| SCHEMBL4046466 | 0.88 | NR1H4 (1.00) | NR1H4CHRNA7BACE1MEN1KMT2A | |
| SCHEMBL5084423 | 0.86 | MAOB (0.80) | NR1H4NFE2L2ABCG2MAPTALDH1A1 | |
| SCHEMBL5084427 | 0.86 | MAOB (0.80) | NR1H4NFE2L2ABCG2MAPTALDH1A1 | |
| SCHEMBL12542565 | 0.84 | CHRNA7 (0.69) | NR1H4CHRNA7MEN1KMT2AABCG2 | |
| SCHEMBL12542567 | 0.84 | CHRNA7 (0.69) | NR1H4CHRNA7MEN1KMT2AABCG2 | |
| SCHEMBL4864045 | 0.83 | NFE2L2 (0.72) | NR1H4NFE2L2MEN1KMT2AABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9763961-B2 | Compositions that modulate the activity of estrogen receptors and estrogen-related receptors and methods for use | CITY OF HOPE (US) | 2017-09-19 | — | — | US | disclosed |
| US-9763961-B2 | Compositions that modulate the activity of estrogen receptors and estrogen-related receptors and methods for use | CITY OF HOPE (US) | 2017-09-19 | — | — | US | disclosed |
| US-9763961-B2 | Compositions that modulate the activity of estrogen receptors and estrogen-related receptors and methods for use | CITY OF HOPE (US) | 2017-09-19 | — | — | US | disclosed |
| WO-2017132135-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-08-03 | — | — | WO | disclosed |
| EP-1888174-B1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20100279987-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | SALIOU CLAUDE | 2010-11-04 | — | — | US | disclosed |
| US-20100279987-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | SALIOU CLAUDE | 2010-11-04 | — | — | US | disclosed |
| US-7781410-B2 | Compositions containing chalcones and use thereof | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781410-B2 | Compositions containing chalcones and use thereof | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20090124688-A1 | Prostaglandin reductase inhibitors | ABGENOMICS CORPORATION (TW) | 2009-05-14 | — | — | US | disclosed |
| US-20080032938-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | JOHNSON & JOHNSON CONSUMER INC. | 2008-02-07 | — | — | US | disclosed |
| US-20080032938-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | JOHNSON & JOHNSON CONSUMER INC. | 2008-02-07 | — | — | US | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007082178-A2 | PROSTAGLANDIN REDUCTASE INHIBITORS | ABGENOMICS CORPORATION (TW) | 2007-07-19 | — | — | WO | disclosed |
| EP-1803809-A2 | Modulation of peroxisome proliferator-activated receptors | Abgenomics Corporation (TW) | 2007-07-04 | — | — | EP | disclosed |
| US-20070037193-A1 | Modulation of peroxisome proliferator-activated receptors | ABGENOMICS CORPORATION (TW) | 2007-02-15 | — | — | US | disclosed |
| US-20070037193-A1 | Modulation of peroxisome proliferator-activated receptors | ABGENOMICS CORPORATION (TW) | 2007-02-15 | — | — | US | disclosed |
| WO-2006127539-A1 | USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | 2006-11-30 | — | — | US | disclosed |
| US-20060241094-A1 | Compositions that modulate the activity of estrogen receptors and estrogen-related receptors and methods for use | CITY OF HOPE | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | NR1H4 32/4885CHRNA7 684/4885BACE1 1856/4885 |
| US-20070037193-A1 | Modulation of peroxisome proliferator-activated receptors | PPARG, PPARA, PPARD | NR1H4 67/4885CHRNA7 2033/4885BACE1 2787/4885 |
| US-20080032938-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | CYP17A1, HSD17B7, CUTA | NR1H4 124/4885CHRNA7 4596/4885BACE1 2213/4885 |
| US-20060270614-A1 | Use of chalcones for the treatment of viral disorders | HAVCR2, HMGB3, EIF2AK2 | NR1H4 704/4885CHRNA7 4811/4885BACE1 3952/4885 |
| US-20060241094-A1 | Compositions that modulate the activity of estrogen receptors and estrogen-related receptors and methods for use | ESR2, ESRRA, ESRRB | NR1H4 45/4885CHRNA7 272/4885BACE1 2724/4885 |
| US-20100279987-A1 | COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF | CYP17A1, HSD17B7, CUTA | NR1H4 124/4885CHRNA7 4596/4885BACE1 2213/4885 |
| US-20090124688-A1 | Prostaglandin reductase inhibitors | PTGIR, PTGDR, PTGDR2 | NR1H4 169/4885CHRNA7 3619/4885BACE1 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.